Factor Xa Affecting Patents (Class 514/14.4)
-
Patent number: 11028382Abstract: The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.Type: GrantFiled: June 8, 2020Date of Patent: June 8, 2021Assignee: Alexion Pharmaceuticals, Inc.Inventors: Juan Wang, Gregory A. Sacha, Phuong M. Nguyen
-
Patent number: 9062298Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: GrantFiled: May 7, 2013Date of Patent: June 23, 2015Assignee: Portola Pharmaceuticals, Inc.Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
-
Patent number: 9056106Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: GrantFiled: July 14, 2010Date of Patent: June 16, 2015Assignee: Portola Pharmaceuticals, Inc.Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
-
Patent number: 9023796Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: GrantFiled: May 7, 2013Date of Patent: May 5, 2015Assignee: Portola Pharmaceuticals, Inc.Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
-
Publication number: 20150025011Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: ApplicationFiled: June 30, 2014Publication date: January 22, 2015Inventors: UMA SINHA, GENMIN LU, ATHIWAT HUTCHALEELAHA, STANLEY J. HOLLENBACH
-
Patent number: 8912143Abstract: The present invention provides long half life genetically modified TFPI sequences (LTFPI) for anticoagulation. On the genetically modified TFPI sequence, the lysine at the carboxy-terminal sites 241, 254, 260 and 261 are replaced by alanin and the amino acid asparagine at glycosylation sites 117, 167, 228 and the amino acids serine and threonine at glycosylation sites 174 and 175 are substitutionally mutated. The present invention also provides methods of making the LTFPI through high efficient LTFPI expression from yeast production system.Type: GrantFiled: November 16, 2011Date of Patent: December 16, 2014Assignee: Fudan UniversityInventors: Duan Ma, Jingui Mu, Jiping Wang, Huijun Wang, Wang Liang
-
Publication number: 20140296147Abstract: Methods of inhibiting, treating or preventing blood loss in a subject undergoing surgery through the administration of an effective amount of the novel serine protease inhibitor MDCO-2010 or its salts or esters are disclosed.Type: ApplicationFiled: October 5, 2012Publication date: October 2, 2014Inventors: Andreas Van De Locht, Wulf Dietrich, Lars Englberger, Peter Villiger, John Villiger
-
Patent number: 8815250Abstract: The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.Type: GrantFiled: March 11, 2013Date of Patent: August 26, 2014Assignee: Biogen Idec Hemophilia Inc.Inventors: Daniel S. Rivera, Robert T. Peters, Alan J. Bitonti
-
Patent number: 8658597Abstract: The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature.Type: GrantFiled: March 19, 2009Date of Patent: February 25, 2014Assignee: Novo Nordisk HealthCare AGInventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt
-
Publication number: 20130209444Abstract: The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.Type: ApplicationFiled: January 30, 2013Publication date: August 15, 2013Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Baxter International Inc., Baxter Healthcare S.A.
-
Patent number: 8486398Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.Type: GrantFiled: January 20, 2011Date of Patent: July 16, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Joanne Van Ryn, John Edward Park, Norbert Hauel, Ulrich Kunz, Tobias Litzenburger, Keith Canada, Sanjaya Singh, Alisa Waterman
-
Patent number: 8455441Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: GrantFiled: March 7, 2012Date of Patent: June 4, 2013Assignee: Portola Pharmaceuticals, Inc.Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
-
Patent number: 8455439Abstract: The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or reduce bleeding in a subject. The antidotes described herein have reduced or no intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is or will be undergoing anticoagulant therapy with a factor Xa inhibitor.Type: GrantFiled: November 11, 2009Date of Patent: June 4, 2013Assignee: Portola Pharmaceuticals, Inc.Inventors: Genmin Lu, Uma Sinha
-
Patent number: 8455440Abstract: The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.Type: GrantFiled: August 19, 2011Date of Patent: June 4, 2013Assignee: Millennium Pharmaceuticals, Inc.Inventors: Uma Sinha, Stanley J. Hollenbach, Patrick Andre
-
Patent number: 8399648Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: April 13, 2012Date of Patent: March 19, 2013Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik Ian Tucker, Stephen Raymond Hanson, David Gailani
-
Patent number: 8388959Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: GrantFiled: December 18, 2009Date of Patent: March 5, 2013Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, David Gailani
-
Publication number: 20120252743Abstract: The invention provides methods of making and using compounds of the formula: or a pharmaceutically acceptable salt thereof; wherein n is an integer between 1 and 2 inclusively; m is an integer between 0 and 2 inclusively; X is selected from the group consisting of CH or N; R1 is selected from the group consisting of —CH2NH2, and R2 is selected from the group consisting of —H, —OH, —NH2 and acetyl; R3 is selected from the group consisting of —H, benzyloxycarbonyl and benzylsulfonyl; and R4 is selected from the group consisting of —OH, wherein p is an integer between 0 and 2 inclusively, Y is selected from the group consisting of —O—, —S—, —S(?O)—, —SO2—, methylene, —CH(OH)—, —CH(NH2)—, —CH(CH2—OH)—, —CH(CH2—NH2)— or —N(R6)—, R5 is selected from the group consisting of —H or a simple (C1-C3) alkyl and R6 is selected from the group consisting of —H, a simple (C1-C3) alkyl or a simple (C1-C3) acyl.Type: ApplicationFiled: December 21, 2011Publication date: October 4, 2012Applicant: The Medicines Company (Leipzig) GmbHInventors: Peter Herold, Stjepan Jelakovic, Mohammed Daghish, Claudia Reichelt, Alexander Schulze, Andrea Schweinitz, Friedrich-Alexander Ludwig, Adel Rafai Far, Ting Kang
-
Patent number: 8268783Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: GrantFiled: March 29, 2010Date of Patent: September 18, 2012Assignee: Portola Pharmaceuticals, Inc.Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley
-
Patent number: 8236316Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: November 21, 2008Date of Patent: August 7, 2012Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik Ian Tucker, Stephen Raymond Hanson, David Gailani
-
Patent number: 8168753Abstract: The invention relates to factor X analogues containing the thrombin-cleavable sequence Pro-Arg-Ala in place of the-sequence Thr-Arg-Ile of the activation site of native factor X. These factor X analogues can be used to obtain procoagulant medicinal products.Type: GrantFiled: June 30, 2003Date of Patent: May 1, 2012Assignee: Institut National de la Sante et de la Recherche MedicaleInventors: Virginie Louvain, Elsa Bianchini, Pierre-Emmanuel Marque, Claire Calmel-Tareau, Martine Aiach, Bernard Le Bonniec
-
Patent number: 8153590Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: GrantFiled: September 26, 2008Date of Patent: April 10, 2012Assignee: Portola Pharmaceuticals, Inc.Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
-
Patent number: 8124587Abstract: 2-(Aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of coagulation factor Xa are provided. The compounds are suitable for the treatment and prophylaxis of cardiovascular and thrombotic events.Type: GrantFiled: September 18, 2006Date of Patent: February 28, 2012Assignee: The Medicines Company (Leipzig) GmbHInventors: Torsten Steinmetzer, Daniel Doennecke, Andrea Schweinitz, Anne Stuerzebecher, Joerg Stuerzebecher
-
Patent number: 8062635Abstract: The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X, and functionally substitute for blood coagulation factor VIII/activated blood coagulation factor VIII which enhances the enzymatic reaction.Type: GrantFiled: October 8, 2004Date of Patent: November 22, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kunihiro Hattori, Tetsuo Kojima, Taro Miyazaki, Tetsuhiro Soeda
-
Publication number: 20110237512Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.Type: ApplicationFiled: September 29, 2010Publication date: September 29, 2011Inventor: Kirk W. Johnson
-
Publication number: 20110172156Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.Type: ApplicationFiled: January 13, 2011Publication date: July 14, 2011Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger
-
Publication number: 20110070288Abstract: The present invention is directed to a hemostatic composite structure having a bioabsorbable fabric or non-woven substrate having at least two major oppositely facing surface areas and a continuous non-porous polymer-based film that is laminated on one major surface of said substrate. The bioabsorbable fabric substrate can be an oxidized polysaccharide and/or the non-woven substrate can be made from bioabsorbable, non-cellulosic derived polymers. The continuous non-porous polymer based film can be a bioabsorbable polymer. The present invention also relates to a method for providing hemostasis by applying a composite structure described herein onto a wound site in need of a hemostatic device wherein a major surface of the substrate without the film layer is applied onto the wound site.Type: ApplicationFiled: September 22, 2009Publication date: March 24, 2011Inventor: SASA ANDJELIC